BioReliance Updates Big Blue Mouse Assay Service

Article

BioReliance updates Big Blue Mouse Assay service to meet OECD test requirements.


SPOTLIGHT EVENT

IVT’s 19th AnnualValidation Week

RELATED ARTICLES

More in GMPs/Validation

BioReliance

, SAFC’s biologics and early-development services business, has qualified the Big Blue Mouse Transgenic Rodent Mutation (TRM) assay to meet the new Organization for Economic Co-Operation and Development (OECD) Test Guideline 488 requirements for evaluation of

in vivo

mutagenicity.

Big Blue is identified in OECD Test Guideline 488 and recommended by the European Chemicals Agency as an accepted assay for evaluating mutagenicity in somatic and male germ cell tissues.

BioReliance acquired the exclusive ownership of the Big Blue TRM assay and rodents from Agilent in March 2013.

Source: BioReliance

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content